Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.

Jensterle M, Pirš B, Goričar K, Dolžan V, Janež A

European journal of clinical pharmacology21 May 2015Cited by 65 (Europe PMC)

PMID25991051DOI10.1007/s00228-015-1868-1PepBankPUB-25991051

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In obese women with PCOS, twenty of 57 were strong responders to 12 weeks of liraglutide, losing 5% or more of their initial body weight.
In plain wordsIn obese women with PCOS, twenty of 57 lost 5% or more of their body weight over 12 weeks of liraglutide.
Peptide
Liraglutide
Outcome
Not applicableStrong responders (weight loss of 5% or more)
Study
n = 57
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Twenty out of 57 subjects were strong responders and lost 7.38 ± 1.74 compared to 2.11 ± 2.17 kg lost in poor responders.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven obese women with PCOS (aged 30.7 ± 7.0, BMI 38.6 ± 5.3 kg/m(2)) were assigned to liraglutide 1.2 mg QD s.c. for 12 weeks and classified as strong responders regarding weight loss if they lost 5% or more of their initial body weight.
Report a problemFND-2599105101
02HumanNon-randomized trialEfficacy outcome
In obese women with PCOS, strong responders lost 7.38 ± 1.74 kg on liraglutide, compared with 2.11 ± 2.17 kg in poor responders.
In plain wordsIn obese women with PCOS, strong responders to liraglutide lost far more weight than poor responders.
Peptide
Liraglutide
Outcome
DecreaseWeight loss in strong responders
Study
n = 57
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Weight loss
7.38 kg
strong responders
Weight loss
2.11 kg
poor responders
Source sentences
Summary
lost 7.38 ± 1.74 compared to 2.11 ± 2.17 kg lost in poor responders.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven obese women with PCOS (aged 30.7 ± 7.0, BMI 38.6 ± 5.3 kg/m(2)) were assigned to liraglutide 1.2 mg QD s.c. for 12 weeks and classified as strong responders regarding weight loss if they lost 5% or more of their initial body weight.
Report a problemFND-2599105102
03HumanNon-randomized trialMechanism
In obese women with PCOS, carriers of at least one polymorphic rs10305420 allele had a poorer weight response to liraglutide than carriers of two wild type alleles.
In plain wordsIn obese women with PCOS, carrying a variant of the GLP-1 receptor gene (rs10305420) was linked to a weaker weight response to liraglutide.
Peptide
Liraglutide
Outcome
DecreaseGLP-1R rs10305420 polymorphism and weight response
Study
n = 57
Comparator
Carriers of two wild type alleles
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Odds ratio for strong response
0.27 NA
rs10305420 variant carriers
Source sentences
Summary
Carriers of at least one polymorphic rs10305420 allele had poor treatment response compared to carriers of two wild type alleles (OR = 0.27, 95% CI = 0.09-0.85, P = 0.025).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven obese women with PCOS (aged 30.7 ± 7.0, BMI 38.6 ± 5.3 kg/m(2)) were assigned to liraglutide 1.2 mg QD s.c. for 12 weeks and classified as strong responders regarding weight loss if they lost 5% or more of their initial body weight.
Report a problemFND-2599105103
04HumanNon-randomized trialMechanism
In obese women with PCOS, carriers of at least one polymorphic rs6923761 allele tended to respond more strongly to liraglutide, but the difference was not significant.
In plain wordsIn obese women with PCOS, a variant of the GLP-1 receptor gene (rs6923761) was not significantly linked to a stronger weight response to liraglutide.
Peptide
Liraglutide
Outcome
No significant changeGLP-1R rs6923761 polymorphism and weight response
Study
n = 57
Comparator
Carriers of two wild type alleles
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Odds ratio for strong response
3.06 NA
rs6923761 variant carriers
Source sentences
Summary
Carriers of at least one polymorphic rs6923761 allele tended to have stronger treatment response compared to carriers of two wild type alleles (OR = 3.06, 95% CI = 0.96-9.74, P = 0.058).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven obese women with PCOS (aged 30.7 ± 7.0, BMI 38.6 ± 5.3 kg/m(2)) were assigned to liraglutide 1.2 mg QD s.c. for 12 weeks and classified as strong responders regarding weight loss if they lost 5% or more of their initial body weight.
Report a problemFND-2599105104
05HumanNon-randomized trialEfficacy outcome
In obese women with PCOS, fasting glucose decreased comparably from baseline in strong and poor responders on liraglutide.
In plain wordsIn obese women with PCOS, liraglutide was linked to lower fasting glucose in both strong and poor weight responders.
Peptide
Liraglutide
Outcome
DecreaseFasting glucose
Study
n = 57
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Fasting glucose and glucose after oral glucose tolerance test (OGTT) comparably decreased in both groups when compared to baseline
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven obese women with PCOS (aged 30.7 ± 7.0, BMI 38.6 ± 5.3 kg/m(2)) were assigned to liraglutide 1.2 mg QD s.c. for 12 weeks and classified as strong responders regarding weight loss if they lost 5% or more of their initial body weight.
Report a problemFND-2599105105
06HumanNon-randomized trialEfficacy outcome
In obese women with PCOS, glucose after an oral glucose tolerance test decreased comparably from baseline in strong and poor responders on liraglutide.
In plain wordsIn obese women with PCOS, liraglutide was linked to lower glucose after a sugar drink in both strong and poor weight responders.
Peptide
Liraglutide
Outcome
DecreaseGlucose after oral glucose tolerance test
Study
n = 57
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Fasting glucose and glucose after oral glucose tolerance test (OGTT) comparably decreased in both groups when compared to baseline
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven obese women with PCOS (aged 30.7 ± 7.0, BMI 38.6 ± 5.3 kg/m(2)) were assigned to liraglutide 1.2 mg QD s.c. for 12 weeks and classified as strong responders regarding weight loss if they lost 5% or more of their initial body weight.
Report a problemFND-2599105106
07HumanNon-randomized trialEfficacy outcome
In obese women with PCOS, no within-treatment differences in androgen profile were found after 12 weeks of liraglutide.
In plain wordsIn obese women with PCOS, 12 weeks of liraglutide did not change male-type hormone levels.
Peptide
Liraglutide
Outcome
No significant changeAndrogen profile
Study
n = 57
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
whereas no within treatment differences were found in androgen profile.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven obese women with PCOS (aged 30.7 ± 7.0, BMI 38.6 ± 5.3 kg/m(2)) were assigned to liraglutide 1.2 mg QD s.c. for 12 weeks and classified as strong responders regarding weight loss if they lost 5% or more of their initial body weight.
Report a problemFND-2599105107
08HumanNon-randomized trialSafety outcome
In obese women with PCOS on liraglutide, gastrointestinal adverse events were transient and balanced between strong and poor responders.
In plain wordsIn obese women with PCOS on liraglutide, stomach and gut side effects were short-lived and similar in strong and poor responders.
Peptide
Liraglutide
Outcome
No significant changeGastrointestinal adverse events
Study
n = 57
Comparator
Poor responders
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Gastrointestinal adverse events were transit and balanced between strong and poor responders.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-seven obese women with PCOS (aged 30.7 ± 7.0, BMI 38.6 ± 5.3 kg/m(2)) were assigned to liraglutide 1.2 mg QD s.c. for 12 weeks and classified as strong responders regarding weight loss if they lost 5% or more of their initial body weight.
Report a problemFND-2599105108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.